Dr. Reddy’s Laboratories Ltd. has announced the launch of Ramelteon Tablets, 8 mg, a therapeutically equivalent generic version of Rozerem® (ramelteon, 8 mg) Tablets, approved by the U.S. Food and Drug Administration (USFDA).

The Rozerem® brand had U.S. sales of approximately $91.3 million MAT for the most recent twelve months ending in May 2019 according to IQVIA Health.

Dr. Reddy’s Ramelteon Tablets are available as 8 mg tablets in bottle count sizes of 30, 100, and 1000.

Rozerem® is a trademark of Takeda Pharmaceutical Company Limited.